Company / Operating Income
BridgeBio Pharma, Inc. Operating Income History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$523.4M
FY2025
5-year range
-$593.0M / -$266.2M
FY2021-FY2025
Trend
+11.7%
vs FY2024
Sector context
#188 of 204
Health Care
What the data says
Among 204 Health Care companies, BridgeBio Pharma, Inc. is in the bottom 8% for operating income. Operating Income returned to growth in FY2025 after 3 years of decline, reaching -$523M.
Based on SEC 10-K filings.
-$523M in FY2025.
Improved from -$577M to -$523M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 204This company -$523.4M Sector average $107.8M
▼
-585.8% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 11.7% year-over-year.
- Ranks #188 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2017.
- Lowest operating income in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$523.4M | +11.7% |
| FY2024 | -$593.0M | -2.8% |
| FY2023 | -$576.6M | -12.6% |
| FY2022 | -$512.2M | -92.4% |
| FY2021 | -$266.2M | +43.9% |
| FY2020 | -$474.5M | -78.2% |
| FY2019 | -$266.2M | -45.0% |
| FY2018 | -$183.7M | -318.8% |
| FY2017 | -$43.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026